AntriaBio (ANTE)
ANTE
Endocrinology
BiotechSign Signal Grade
F
Signal Grade
0.1/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Publications
10
Clinical Activity
0
Pipeline Overview
- Therapeutic Focus
- Endocrinologysrc
Clinical Trial Activity
0
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
2
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Recent Publications
- Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes. — Diabetes Technol Ther 2018 Feb PMID 29355435
- Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4). — Diabetes Obes Metab 2018 Jan PMID 28661585
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for AntriaBio.
Full ANTE Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.